A dose escalation and phase II study of gemtuzumab ozogamicin (CMA-676; Mylotarg) with high-dose cytarabine for patients with refractory or relapsed acute myeloid leukemia (AML)

Trial Profile

A dose escalation and phase II study of gemtuzumab ozogamicin (CMA-676; Mylotarg) with high-dose cytarabine for patients with refractory or relapsed acute myeloid leukemia (AML)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2016

At a glance

  • Drugs Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top